このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Scorpius Holdings マネジメント

マネジメント基準チェック /44

Scorpius Holdings'の CEO はJeff Wolfで、 Aug2008年に任命され、の在任期間は 15.83年です。の年間総報酬は$ 575.00Kで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.11%を直接所有しており、その価値は$ 30.63K 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と7.4年です。

主要情報

Jeff Wolf

最高経営責任者

US$575.0k

報酬総額

CEO給与比率	100.0%
CEO在任期間	15.8yrs
CEOの所有権	1.1%
経営陣の平均在職期間	4.8yrs
取締役会の平均在任期間	7.4yrs

経営陣の近況

Recent updates

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Dec 28

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Sep 02

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Mar 07

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Jan 13

Heat Biologics signs a licensing agreement; Appoints new CFO

Jan 06

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

Dec 16

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Nov 20

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 02

CEO報酬分析

Scorpius Holdings の収益と比較して、Jeff Wolf の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$575k	US$575k	-US$40m
Sep 30 2023	n/a	n/a	-US$53m
Jun 30 2023	n/a	n/a	-US$52m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$562k	-US$41m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$6m	US$540k	-US$35m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$6m	US$440k	-US$26m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$3m	US$428k	-US$20m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$1m	US$417k	-US$16m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	US$964k	US$417k	-US$12m

報酬と市場: Jeffの総報酬 ($USD 575.00K ) は、 US市場 ($USD 673.68K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jeffの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jeff Wolf (61 yo)

15.8yrs

在職期間

US$575,000

報酬

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D. founded Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (formerly known as Heat Biologics, Inc.) in August 2008 and has been Chairman...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Jeffrey Wolf	Founder	15.8yrs	US$575.00k	1.11% $ 43.8k
William Ostrander	CFO & Secretary	4.8yrs	US$375.00k	0.0067% $ 264.1
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
George Peoples	Chief Medical Advisor	7.2yrs	データなし	データなし
Ania Szymanska	Site Head of Quality	less than a year	データなし	データなし
Joe Payne	President & COO of Scorpius BioManufacturing	less than a year	データなし	データなし

4.8yrs

平均在職期間

経験豊富な経営陣: SCPXの経営陣は経験豊富であると考えられます ( 4.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Jeffrey Wolf	Founder	15.8yrs	US$575.00k	1.11% $ 43.8k
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
John K. Prendergast	Independent Lead Director	8.2yrs	US$301.00k	0.24% $ 9.5k
John Monahan	Independent Director	14.6yrs	US$81.50k	0.000070% $ 2.8
Llew Keltner	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Anthony Tolcher	Scientific Advisory Board Member	6.3yrs	データなし	データなし
Roger Cohen	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Richard Myers	Chairman of BioThreat Advisory Board	2.1yrs	データなし	データなし
Gary Acton	Member of Scientific & Clinical Advisory Board	no data	データなし	データなし
Robert Negrin	Member of Scientific Advisory Board	6.7yrs	データなし	データなし
Edward Smith	Independent Director	13.6yrs	US$92.50k	0.00014% $ 5.5
Robert Levy	Member of Scientific Advisory Board	6.7yrs	データなし	データなし

7.4yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: SCPXの取締役会は経験豊富であると考えられます ( 7.4年の平均在任期間)。

Scorpius Holdings マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Recent updates

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Price target decreased by 9.1% to US$10.00

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Price target decreased to US$21.83

Price target decreased to US$23.83

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Consensus forecasts updated

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold US$205k worth of stock

Consensus forecasts updated

Consensus revenue estimates fall to US$1.98m

Heat Biologics names Anthony Manning as chief scientific advisor

Price target decreased to US$24.67

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Heat Biologics EPS misses by $0.01, misses on revenue

We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

New 90-day high: US$8.76

Price target lowered to US$27.30

Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

Heat Biologics signs a licensing agreement; Appoints new CFO

New 90-day low: US$5.28

Analysts update estimates

Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19

New 90-day low: US$1.01

Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma

Earnings released

Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

マネジメント基準チェック /44